RT @MeralElRamahiMD: Post-Hoc of the ASCORE trial showed the following b/l characteristics were most likely associated w
Tweet Content
Post-Hoc of the ASCORE trial showed the following b/l characteristics were most likely associated with remission (per DAS28, SDAI, CDAI) in mod-severe RA patients treated w/ SQ Abatacept:
⭐️Seropositivity
⭐️no prior bMDARD use
⭐️low HAQ-DI
⭐️low BMI
Abst#1228 #ACR21 @Rheumnow https://t.co/NvJoSWScZs
Show on Archive Page
On
Display in Search Results
On
PDQ
Off